Indocyanine green and Visual acuity reduced - a phase IV clinical study of FDA data

Summary:

Visual acuity reduced is reported as a side effect among people who take Indocyanine green (indocyanine green), especially for people who are male, 60+ old, also take Lucentis, and have Polypoidal choroidal vasculopathy.

The phase IV clinical study analyzes which people have Visual acuity reduced when taking Indocyanine green. It is created by eHealthMe based on reports of 122 people who have side effects when taking Indocyanine green from the FDA, and is updated regularly.

What is Indocyanine green?

Indocyanine green has active ingredients of indocyanine green. eHealthMe is studying from 122 Indocyanine green users. Check the latest studies of Indocyanine green.

What is Visual acuity reduced?

Visual acuity reduced (reduced clearness of vision) is found to be associated with 1,493 drugs and 1,887 conditions by eHealthMe. Check the latest studies of Visual acuity reduced.

On Jul, 13, 2026

122 people reported to have side effects when taking Indocyanine green.
Among them, 12 people (9.84%) have Visual acuity reduced.

Could Indocyanine green cause Visual acuity reduced?

Among these 12 people:

What is the gender of people who have Visual acuity reduced when taking Indocyanine green? *

female: 10 %
male: 90 %

What is the age of people who have Visual acuity reduced when taking Indocyanine green? *

What are other drugs people take besides Indocyanine green? *

Lucentis: 12 people, 100.00%
Visudyne: 10 people, 83.33%
Eylea: 6 people, 50.00%

What are other side effects people have besides Visual acuity reduced? *

Age-Related Macular Degeneration: 8 people, 66.67%
Urticaria (rash of round, red welts on the skin that itch intensely): 7 people, 58.33%
Disease Progression: 7 people, 58.33%
Contrast Media Allergy (reaction associated with the use of intravenous contrast material during radiology): 7 people, 58.33%
Cataract (clouding of the lens inside the eye): 7 people, 58.33%
Retinal Scar (development of scar tissue on retina): 3 people, 25.00%
Retinal Haemorrhage (bleeding from retina): 3 people, 25.00%
Polypoidal Choroidal Vasculopathy (polyp-like sub-retinal pigment epithelium vascular abnormalities predominantly found in the macula and peripapillary region): 3 people, 25.00%
Drug Resistance (reduction in effectiveness of a drug): 3 people, 25.00%
Vitreous Haemorrhage (intraocular (inside the eye) bleeding): 2 people, 16.67%

What are the existing conditions these people have? *

Polypoidal Choroidal Vasculopathy (polyp-like sub-retinal pigment epithelium vascular abnormalities predominantly found in the macula and peripapillary region): 8 people, 66.67%
Age-Related Macular Degeneration: 6 people, 50.00%
Choroidal Neovascularisation (creation of new blood vessels in vascular layer of eye): 3 people, 25.00%
Retinal Vessel Occlusion (a blockage in one of the small arteries): 1 person, 8.33%
Macular Oedema (fluid and protein deposits collect on or under the macula of the eye (a yellow central area of the retina) and causes it to thicken): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Indocyanine green and have Visual acuity reduced?

- Check whether Visual acuity reduced is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Indocyanine green:

Indocyanine green (122 reports)

Browse all side effects of Indocyanine green:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Visual acuity reduced:

Visual acuity reduced (1,493 drugs)

Browse all the conditions that are associated with Visual acuity reduced:

Visual acuity reduced (1,887 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on indocyanine green (the active ingredients of Indocyanine green) and Indocyanine green (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.